Literature DB >> 15049577

Prostate-specific antigen and screening for prostate cancer.

Misop Han1, Peter H Gann, William J Catalona.   

Abstract

This article discusses prostate-specific antigen (PSA) and screening for prostate cancer. Topics explored include the history of PSA testing, the biology of PSA, clinical uses of PSA testing, improving the accuracy of PSA testing, and controversies in prostate cancer screening.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15049577     DOI: 10.1016/S0025-7125(03)00188-3

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  2 in total

1.  Adenocarcinoma of the prostate presenting as an obstructing rectal mass.

Authors:  P M Boland; R S Dhillon; S D Goldstein; B J O'hara; D M Kastenberg
Journal:  Dig Dis Sci       Date:  2007-04-19       Impact factor: 3.199

2.  3,3'-Diindolylmethane and genistein decrease the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells.

Authors:  Sunyata Smith; Daniel Sepkovic; H Leon Bradlow; Karen J Auborn
Journal:  J Nutr       Date:  2008-12       Impact factor: 4.798

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.